(Q46783516)

25 December 2017

title

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer (English)

1 reference

25 December 2017

1 reference

4

Ursula A Matulonis

1 reference

25 December 2017

author name string

Michael V Seiden

1

1 reference

25 December 2017

Alan N Gordon

2

1 reference

25 December 2017

Diane C Bodurka

3

1 reference

25 December 2017

Richard T Penson

5

1 reference

25 December 2017

Eddie Reed

6

1 reference

25 December 2017

Dave S Alberts

7

1 reference

25 December 2017

Garry Weems

8

1 reference

25 December 2017

Michael Cullen

9

1 reference

25 December 2017

William P McGuire

10

1 reference

25 December 2017

language of work or name

English

0 references

publication date

2 November 2005

1 reference

25 December 2017

published in

Gynecologic Oncology

1 reference

25 December 2017

volume

101

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

55-61

1 reference

25 December 2017

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase II Study of MGI-114 Administered Intravenously for 5 Days Every 28 Days to Patients With Metastatic Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

One-sample multiple testing procedure for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Cone damage in patients receiving high-dose irofulven treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Acute retinal toxicity from the novel anti-tumor agent, Irofulven

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.036

10.1016/J.YGYNO.2005.09.036

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

16260029

1 reference

25 December 2017